View Latest Issue
The management of pediatric pain is multimodal, with the goal of improving function in addition to decreasing pain, said Sharon K. Wrona, DNP, RN-BC, PNP, PMHS, AP-PMN, at the 2015 Annual Conference of the Rheumatology Nurses Society.
In September, the American College of Rheumatology (ACR) released new treatment guidelines for polymyalgia rheumatica (PMR).
The American Board of Internal Medicine (ABIM) has received significant criticism related to the requirements and the increased fees for its maintenance-of-certification (MOC) program.
More than 90% of people with systemic lupus erythematosus (SLE) are women between the ages of 15 and 54 years—encompassing common childbearing years.
The first judicial decision to address the 60-day overpayment rule that is part of the Affordable Care Act and the Fraud Enforcement and Recovery Act was handed down in August by the United States District Court for the Southern District of New York.
Secukinumab 300 mg and 150 mg given subcutaneously achieved significant and sustained reductions in the burden of psoriasis on skin and nails in patients with active psoriatic arthritis (PsA) in the phase 3 FUTURE 2 trial.
Reducing the dose of biologic in patients with rheumatoid arthritis (RA) is feasible, cost-effective, and does not appear to compromise clinical response, according to separate studies presented at the 2015 annual meeting of the European League Against Rheumatism (EULAR).
The US Food and Drug Administration (FDA) has issued draft guidance for the naming of biosimilars. The FDA proposal calls for attachment of 4-letter suffixes to distinguish a biosimilar from the originator product and biosimilars from other biosimilars.
Page 2 of 2
Results 11 - 18 of 18
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology